entertainment -WSS

entertainment

author：comprehensive 2025-09-30 17:29:28 - browse：22

A drug developed by the biotech firm BridgeBio to treat an increasingly common heart condition succeeded in its main goal in a clinical trial, the company said Monday, and also pointed to potential reductions in hospitalization and death.

The results may give the medicine, acoramidis, a path to the market after a failure that led its maker’s stock to plunge in December 2021.

In the time since the initial failure, a rival Pfizer drug has become even more entrenched and another medicine, from Alnylam Pharmaceuticals, has had a successful clinical readout in the heart disease, known as ATTR-CM, in which a defective protein leads clumps to build up in the heart.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Wayne Brady comes out as pansexual: 'Free to love whomever I want'

WSS

In same hospitals, Black patients receive fewer opioids than white patients

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

South Korea throws huge K

Prior authorization will have to move faster under new Biden rule

Elizabeth Holmes banned from government health programs

NIH trials fail to test meaningful long Covid therapies, experts say

knowledge

entertainment

entertainment

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

As demand for Covid shots wanes, Moderna seeks its next success

Man killed during FBI raid in connection with threats against Biden, other officials

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Police still searching for prisoner who escaped from NYC hospital

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Moonlake's readout produced a cash windfall. Risks remain

Man killed during FBI raid in connection with threats against Biden, other officials

focus

EU regulator recommends expanding Mounjaro approval to obesity

American woman, child freed after being kidnapped in Haiti last month

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

EU regulator recommends expanding Mounjaro approval to obesity

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

In same hospitals, Black patients receive fewer opioids than white patients

explore

focus

hotspot

knowledge